Filing Analysis
Reverse Stock Split
Filed Mar 17, 2026
HIGH
Akari Therapeutics announced a 1-for-40 reverse split of its American Depositary Shares (ADSs) by changing the ratio from 1:2,000 to 1:80,000 ordinary shares. The change is scheduled to take effect on March 31, 2026, in an effort to regain or maintain compliance with Nasdaq's minimum bid price requirement.
Red Flags
- Significant 1-for-40 reverse split ratio.
- Explicit mention of uncertainty regarding the ability to satisfy Nasdaq minimum bid price requirements even after the split.
Key Facts
- The ADS ratio will change from one ADS representing 2,000 ordinary shares to one ADS representing 80,000 ordinary shares.
- The action results in a 1-for-40 reverse split of issued and outstanding ADSs.
- The effective date for the ratio change is approximately March 31, 2026.
- The change has no effect on the underlying ordinary shares, only the ADSs.
Securities Offering
Filed Mar 02, 2026
HIGH
Akari Therapeutics held a Special General Meeting on March 2, 2026, where shareholders approved the exercisability of a massive volume of warrants issued in late 2025 and early 2026. These approvals, required by Nasdaq Listing Rule 5635, facilitate the potential issuance of over 26 million American Depositary Shares (ADSs) through Series G, Pre-Funded, and Note Exchange warrants.
Red Flags
- Extreme potential dilution: The warrants approved for exercise represent a significant percentage of the company's total equity (potentially exceeding 50% of current ADS equivalents).
- Reliance on Note Exchange Warrants suggests the company is converting debt to equity to manage its balance sheet.
- The use of Pre-Funded Warrants and Series G Warrants often indicates high-cost capital raising typical of distressed micro-cap entities.
Key Facts
- Shareholders approved the exercisability of Series G Warrants for 10,043,774 ADSs and Placement Agent Warrants for 504,300 ADSs.
- Approved exercisability of Pre-Funded and Series G Warrants for approximately 5.1 million ADSs related to a December 2025 private placement.
- Approved exercisability of Pre-Funded and Note Exchange Warrants for approximately 28.3 million ADSs related to a December 2025 note exchange.
- Total ordinary shares entitled to vote at the meeting was 91,567,009,533 (equivalent to approximately 45.7 million ADSs).
- All resolutions passed with significant majorities, clearing the path for substantial equity dilution.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.